-
Product Insights
Perennial Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Perennial Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Perennial Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Perennial Wind Chaser Power Plant
Perennial Wind Chaser Power Plant is a thermal project located in Oregon, United States. The project is owned and developed by Perennial Power Holdings Inc. The project is currently under construction. Empower your strategies with our Perennial Wind Chaser Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SA-16001 in Allergic Rhinitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SA-16001 in Allergic Rhinitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SA-16001 in Allergic Rhinitis Drug Details: SA-16001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SA-16001 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SA-16001 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SA-16001 in Asthma Drug Details: SA-16001 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Yipiwutai in Allergic Conjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Yipiwutai in Allergic Conjunctivitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Yipiwutai in Allergic Conjunctivitis Drug Details: Yipiwutai is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Food Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Food Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Peanut Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Peanut Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Milk Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Milk Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
Hermiston Generating Plant (HGP)
Hermiston Generating Plant (HGP) is a thermal project located in Oregon, United States. The project is owned by PacifiCorp; Perennial Power Holdings Inc. The project came online in 1996. Empower your strategies with our Hermiston Generating Plant (HGP) report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lirentelimab in Peanut Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lirentelimab in Peanut Allergy Drug Details: Lirentelimab (AK002) is under development for the treatment of...